IRLAB A
6.92
SEK
TODAY
-2.12 %
TODAY SEK
-0.15 SEK
09:54:37
2025-04-28
YEAR LOW
4.25 SEK
YEAR HIGH
16.5 SEK
ATH:
108.09 SEK
MCAP:
358 MSEK

CEO COMMENTS

Kristina Torfgård comments Q4 report 2024

It has been a successful year that has brought us closer to our goal of improving the lives of people living with Parkinson’s disease and other neurodegenerative conditions.”

“I am proud to be part of the IRLAB team and
deeply inspired by the unique combination of ground-breaking research, innovation, and collaboration that permeates the entire company.
Our pipeline is stronger than ever, with our drug
candidates holding the potential to become first-in-class treatments that can transform the lives of millions of people worldwide, along with their loved ones. With the progress we have achieved so far and the exciting opportunities ahead, I confidently look forward to leading IRLAB into the next phase of our growth journey.”

LATEST REPORTS

LATEST PRESS RELEASE
APRIL 25, 2025 / REGULATORY

IRLAB publishes the Annual Report for 2024

Gothenburg, Sweden, April 25, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announced today that the Annual Report for 2024 is published on the company’s website, www.irlab.se.

Read More >
LATEST PRESENTATION
OCTOBER 25, 2024

Presentation at Redeye’s Theme Event Neurology

Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.

Read More >

FINANCIAL CALENDAR

NEXT

July 10, 2024

Interim Report January – June 2024